Objective: To investigate the effect of Gansu granule on patients with chronic hepatitis B (CHB). Method: Eighty-six subjects were randomly divided into observation group and control group (n=43 each). Pegasys were given to the control group

180 μg each time

1 time each week. Based on the pegasys treatment

Gansu granule was added to the observation group

9 g

tid

all for 24 weeks. Interlukin-21 (IL-21) level

hepatitis B virus-DNA (HBV-DNA) and lung function were quantified and measured. Result: The level of HBV-DNA in both groups after the treatment were lower than those before

the observation group were more lower than that in the control group (P<0.05). IL-21 level in both groups after the treatment were higher than before

the level in observation group was higher than that in the control group (P<0.01). Aspartate aminotransferase (AST)

alanine aminotransferase (ALT)

γ-glutamete transpeptidase (GGT) and total bilirubin (Tbil) in the observation group after the treatment were lower than those in the control group (P<0.05

P<0.01)

and albumin (Alb) of the observation group after the treatment were higher than that in the control group (P<0.05). Conclusion: Gansu granule can elevate IL-21 level for the patients with CHB. Gansu granule has anti-HBV function and could protect liver function.